STATEMENT - A MAJOR INVESTMENT BY GLAXOSMITHKLINE WILL SIGNIFICANTLY ADVANCE INNOVATION AND MANUFACTURING IN ONTARIO

STATEMENT - A MAJOR INVESTMENT BY GLAXOSMITHKLINE WILL SIGNIFICANTLY ADVANCE INNOVATION AND MANUFACTURING IN ONTARIO
OTTAWA, June 10, 2011 /CNW/ - Rx&D President Russell Williams made the following statement to complement the announcement made yesterday by GlaxoSmithKline Inc. of an investment of over $30 million in pharmaceutical innovation and advanced manufacturing in Mississauga, Ontario and the Ontario Ministry of Research and Innovation's investment of $3.55 million.

"Yesterday's announcement reflects a shared commitment by Canada's research-based pharmaceutical industry and the Government of Ontario to invest in pharmaceutical innovation and advanced manufacturing.

"The chance to innovate and improve patient health and quality of life through research and innovation is what motivates all those active in the life science community. In Ontario this is reflected in lasting strategic partnerships that include not only government and industry, but also universities, health care professionals and the research-based pharmaceutical community.

"This major investment from GlaxoSmithKline is a perfect example of innovation investment. It provides a highly effective way of progressing and commercializing cutting-edge research. By expanding the Mississauga manufacturing facility and enabling the production of various dermatological and foam products, the joint Ministry and GlaxoSmithKline's investment will create 70 jobs and protect another 300 jobs in Ontario and will make the site more competitive in Canada and globally for new production mandates.

"It is by working together that we can consolidate the position of Ontario and Canada as leaders and providers of health care solutions to people across the country and throughout the world.

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents 15,000 men and women working for 50 member companies and invests more than $1 billion in research and development each year to fuel Canada's knowledge-based economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.

 

 


For further information:
Christine Choury
Media Relations
Telephone: 613-236-0455
E-mail: [email protected]

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.